李粉婷 高欣欣 王 新 謝華紅
第四軍醫(yī)大學(xué)西京消化病院(710032)
經(jīng)口內(nèi)鏡下肌切開術(shù)治療賁門失弛緩癥的現(xiàn)狀和進(jìn)展
李粉婷 高欣欣 王 新 謝華紅*
第四軍醫(yī)大學(xué)西京消化病院(710032)
賁門失弛緩癥是由食管-胃交界處神經(jīng)肌肉功能障礙所致的一種食管動(dòng)力障礙的功能性疾病,主要特征為食管缺乏蠕動(dòng)、食管下括約肌松弛受限。目前治療方法包括肉毒素治療、支架植入、腹腔鏡Heller肌切開術(shù)和內(nèi)鏡下球囊擴(kuò)張術(shù),但這些治療手段存在短期內(nèi)易復(fù)發(fā)、損傷較大等不足。隨著內(nèi)鏡技術(shù)的不斷發(fā)展,新型微創(chuàng)術(shù)式經(jīng)口內(nèi)鏡下肌切開術(shù)(POEM)在臨床上得到廣泛應(yīng)用,亦可用于一些特殊患者,如Ⅲ型賁門失弛緩癥、高齡、小兒、乙狀結(jié)腸型賁門失弛緩癥等。本文就POEM治療賁門失弛緩癥的現(xiàn)狀和進(jìn)展作一綜述。
賁門失弛緩; 經(jīng)口內(nèi)鏡下肌切開術(shù); 治療; 手術(shù)后并發(fā)癥
賁門失弛緩癥是由食管-胃交界處神經(jīng)肌肉功能障礙所致的一種食管動(dòng)力障礙的功能性疾病,主要特征為食管缺乏蠕動(dòng)、食管下括約肌松弛受限。目前治療方法包括肉毒素治療、支架植入、腹腔鏡下Heller肌切開術(shù)(laparoscopic Heller myotomy, LHM)以及內(nèi)鏡下球囊擴(kuò)張術(shù),但這些治療手段存在易復(fù)發(fā)、損傷較大等不足。近來,隨著內(nèi)鏡技術(shù)的發(fā)展,經(jīng)口內(nèi)鏡下肌切開術(shù)(peroral endoscopic myotomy, POEM)在臨床上備受關(guān)注。本文就POEM治療賁門失弛緩癥的現(xiàn)狀和進(jìn)展作一綜述。
賁門失弛緩癥臨床主要表現(xiàn)為進(jìn)行性吞咽困難、燒心、反流或嘔吐、非心源性胸痛等[1]。對(duì)于賁門失弛緩癥患者,大多數(shù)治療主要為緩解臨床癥狀。肉毒桿菌毒素注射可阻斷神經(jīng)末梢乙酰膽堿釋放,緩解癥狀,但多數(shù)患者在12個(gè)月內(nèi)復(fù)發(fā)或需再次治療。該方法由于給藥劑量較少,并不引起廣泛肌麻痹,因此多用于老年或手術(shù)風(fēng)險(xiǎn)較高的患者[1]。Campos等[2]進(jìn)行的meta分析表明,球囊擴(kuò)張可使賁門失弛緩癥患者食管肌纖維破壞,從而達(dá)到緩解臨床癥狀的目的,有效率為54%~91%,但約33%的患者出現(xiàn)并發(fā)癥,食管穿孔率可高達(dá)16%[3],遠(yuǎn)期療效顯示僅40%的患者可獲得5年緩解期[4]。支架植入術(shù)治療賁門失弛緩癥的有效率為83.3%,但支架移位的發(fā)生率為5.3%,胸痛的發(fā)生率為38.7%[5]。LHM可通過分離食管下括約肌的環(huán)行肌纖維達(dá)到治療效果,其有效率為88%~95%,并發(fā)癥發(fā)生率為6.3%,對(duì)于Ⅱ型賁門失弛緩癥患者療效最佳,且優(yōu)于球囊擴(kuò)張術(shù),常作為一線治療手段[3,6]。隨著內(nèi)鏡技術(shù)的不斷發(fā)展,新型微創(chuàng)術(shù)式POEM在臨床上得到廣泛應(yīng)用。
1. 基本流程:所有患者術(shù)前均行氣管插管和全身麻醉,胃鏡前端套透明帽,進(jìn)鏡至距胃食管交界處上方8~10 cm,黏膜下注射0.3%靛胭脂+0.9% NaCl+腎上腺素,T型刀切開2~3 cm,暴露黏膜下層,建立黏膜下隧道至賁門下3 cm,于入口處向下沿隧道縱行切開所有環(huán)形肌束,避免損傷縱行肌束,切開長(zhǎng)度不少于10 cm,最后以鈦夾夾閉入口。胃食管交界位置可根據(jù)進(jìn)鏡深度距門齒的距離進(jìn)行判斷,若黏膜下腔隙狹小且阻力較高,鏡身通過后出現(xiàn)落空感亦提示已進(jìn)鏡達(dá)胃食管交界處[7]。由于T型刀不具有注射功能,操作過程中需不斷更換刀具、注射針,因此已逐漸被海博刀所取代。
2. 術(shù)式改進(jìn):Cai等[8]采用海博刀對(duì)100例賁門失弛緩癥患者進(jìn)行內(nèi)鏡下治療,海博刀具有水束分離技術(shù)和內(nèi)鏡下電切技術(shù),高壓無針式水束可將黏膜抬起分離,無需頻繁更換手術(shù)器械,與常規(guī)切除術(shù)相比,可明顯縮短手術(shù)時(shí)間,該操作在切開內(nèi)側(cè)環(huán)形肌束的同時(shí)切開了外側(cè)縱行肌束,但不增加食管穿孔率。POEM術(shù)中黏膜下隧道的建立占據(jù)了手術(shù)近一半時(shí)間,Liu等[9]改進(jìn)了術(shù)式,省略黏膜下隧道的建立過程,直接進(jìn)行肌切開。改良后的POEM平均用時(shí)僅約30 min,與傳統(tǒng)POEM術(shù)式相比,患者術(shù)中出血量明顯減少。部分賁門失弛緩癥患者食管黏膜發(fā)生炎癥,質(zhì)地較脆,POEM最后進(jìn)行入口關(guān)閉時(shí)難以采用鈦夾夾閉,Yang等[10]在此情況下采用食管金屬支架對(duì)切口進(jìn)行封閉,避免了食管瘺的發(fā)生和需進(jìn)一步進(jìn)行的外科手術(shù)處理,且無嚴(yán)重并發(fā)癥發(fā)生。
臨床研究[11-13]顯示,經(jīng)POEM治療后,約89%~100%患者的臨床癥狀可得到緩解。Barbieri等[14]的meta分析亦得出相似結(jié)論,認(rèn)為POEM可有效緩解賁門失弛緩癥患者癥狀,且具有較高的安全性。Teitelbaum等[15]的研究顯示,在POEM術(shù)后1年的隨訪中,92%的患者獲得手術(shù)成功(Eckardt評(píng)分<4),17%的患者發(fā)生并發(fā)癥,但癥狀較輕,其中15%的患者發(fā)生反流(80%的患者洛杉磯反流性食管炎分級(jí)為B級(jí))。Werner等[16]對(duì)行POEM的賁門失弛緩癥患者進(jìn)行了術(shù)后2年隨訪,發(fā)現(xiàn)96.3%的患者臨床癥狀得到顯著改善,17.7%的患者出現(xiàn)復(fù)發(fā),進(jìn)一步行多因素分析發(fā)現(xiàn),年齡和反流現(xiàn)象與手術(shù)是否成功無關(guān)。晉宏等[17]對(duì)POEM治療賁門失弛緩癥術(shù)后3年的療效進(jìn)行評(píng)估,發(fā)現(xiàn)患者Eckardt評(píng)分、食管下括約肌壓(LESP)、食管下括約肌松弛率與術(shù)前相比顯著改善,提示POEM術(shù)后短中期療效較好。上述研究表明POEM可作為治療賁門失弛緩癥的有效手段。
1. 胃食管反流病(gastroesophageal reflux disease, GERD):GERD是POEM術(shù)后常見并發(fā)癥。研究[7]指出,POEM術(shù)后腐蝕性食管炎的發(fā)生率可達(dá)6%~40%,食管內(nèi)pH值異常的發(fā)生率為20%~40%。臨床上約4.9%~33%的賁門失弛緩癥患者出現(xiàn)反流癥狀,其中80%具有輕度食管炎癥,僅4.89%的患者需進(jìn)行抑酸治療,患者服用抑酸制劑后癥狀可明顯好轉(zhuǎn)。
2. 氣胸:Ren等[18]的研究顯示,POEM術(shù)后氣胸的發(fā)生率可達(dá)25.2%,氣體量較少時(shí)可監(jiān)測(cè)血氧飽和度,但若氣體量>30%則需行穿刺。
3. 氣腹:POEM術(shù)后氣腹的發(fā)生率約為13%,氣體量較大時(shí)需行穿刺治療[12]。
4. 黏膜損傷:POEM術(shù)后食管黏膜損傷的發(fā)生率約為2.7%,但大部分患者癥狀較輕[19]。
5. 出血:POEM術(shù)后出血的發(fā)生率為0.8%~2.5%,癥狀較輕時(shí)可給予對(duì)癥支持治療,出血量較大時(shí)需輸血,預(yù)防術(shù)后出血依賴于術(shù)中仔細(xì)探查和止血[18-20]。
6. 其他:除上述并發(fā)癥外,POEM術(shù)后亦可發(fā)生皮下氣腫、肺部感染等并發(fā)癥。不同報(bào)道中POEM手術(shù)并發(fā)癥的發(fā)生率差異較大,以往認(rèn)為可能與手術(shù)切開長(zhǎng)度、深度以及術(shù)者操作情況有關(guān)。Shiwaku等[21]的研究表明,POEM術(shù)后胃食管反流的發(fā)生與術(shù)中肌肉切開長(zhǎng)度無關(guān),而與食管松弛壓有關(guān)。目前尚未見因POEM術(shù)后并發(fā)癥導(dǎo)致死亡的報(bào)道。
1. POEM與LHM:有學(xué)者[19,22]對(duì)POEM與LHM治療賁門失弛緩癥進(jìn)行比較,結(jié)果顯示LHM與POEM緩解患者臨床癥狀的療效相當(dāng),但行POEM的患者生活質(zhì)量高于行LHM的患者,并且POEM縮短了手術(shù)時(shí)間,術(shù)者可根據(jù)患者的具體狀況選擇食管肌層切開長(zhǎng)度。盡管研究表明POEM與LHM在療效、并發(fā)癥等方面并無明顯差異,但研究多為回顧性臨床試驗(yàn),且隨訪時(shí)間較短。因此,需大樣本量、長(zhǎng)時(shí)間隨訪的前瞻性臨床試驗(yàn)進(jìn)一步驗(yàn)證。外科手術(shù)失敗的患者往往需重新行肌切開術(shù)或食管切除術(shù),但臨床獲益甚微。因此Onimaru等[23]進(jìn)行了一項(xiàng)前瞻性臨床試驗(yàn),納入LHM失敗不能行球囊擴(kuò)張術(shù)的賁門失弛緩癥患者,對(duì)患者進(jìn)行POEM,術(shù)后隨訪3個(gè)月,結(jié)果顯示患者術(shù)后食管內(nèi)壓力明顯下降[(10.9±4.5) mm Hg(1 mm Hg=0.133 kPa)對(duì)(22.1±6.6) mm Hg],Eckardt評(píng)分顯著降低(1.1±1.3對(duì)6.5±1.3)。由此可見,POEM可用于外科手術(shù)失敗的賁門失弛緩癥患者的再次治療。
2. POEM與球囊擴(kuò)張術(shù):球囊擴(kuò)張術(shù)對(duì)賁門失弛緩癥有一定療效,有學(xué)者[24]將此與POEM進(jìn)行比較,結(jié)果顯示術(shù)后3個(gè)月兩組患者均獲得明顯臨床緩解,POEM組患者術(shù)后Eckardt評(píng)分和LESP與球囊擴(kuò)張術(shù)組相比差異無統(tǒng)計(jì)學(xué)意義,但術(shù)后12個(gè)月隨訪發(fā)現(xiàn)球囊擴(kuò)張術(shù)組的Eckardt評(píng)分和LESP顯著高于POEM組[4.23±2.06對(duì)1.18±1.08,P<0.00; (38.27±9.13) mm Hg對(duì)(13.42±5.56) mm Hg,P<0.00]。Ling等[25]對(duì)球囊擴(kuò)張術(shù)失敗的賁門失弛緩癥患者行POEM,該研究表明除手術(shù)時(shí)間有所延長(zhǎng),術(shù)后患者Eckardt評(píng)分、LESP均顯著下降,提示球囊擴(kuò)張術(shù)操作失敗對(duì)后續(xù)行POEM無明顯影響。
1. Ⅲ型賁門失弛緩癥患者:Ⅲ型賁門失弛緩癥患者由于遠(yuǎn)端食管攣縮,臨床治療效果較差。Pandolfino等[6]指出,對(duì)于賁門失弛緩癥患者,球囊擴(kuò)張術(shù)的有效率為70%~90%,LHM有效率為88%~95%,且療效與分型有關(guān):Ⅰ型患者(食管失去蠕動(dòng)能力但無異常壓力)療效與食管擴(kuò)張程度呈負(fù)相關(guān),有效率為81%;Ⅱ型患者(食管失去蠕動(dòng)能力且存在異常高壓)療效較好,有效率為96%;Ⅲ型患者(食管失去蠕動(dòng)能力伴遠(yuǎn)端食管痙攣收縮)療效較差,有效率為66%。Kumbhari等[26]對(duì)Ⅲ型賁門失弛緩癥患者行LHM或POEM療效的對(duì)比研究,結(jié)果顯示POEM組有效率高于LHM組(98.8%對(duì)80.8%),POEM較LHM的手術(shù)時(shí)間明顯縮短(102 min對(duì)264 min),POEM的不良事件發(fā)生率亦較LHM降低(6%對(duì)27%)。
2. 年齡≥65歲的賁門失弛緩癥患者:近年一項(xiàng)臨床研究[27]表明,對(duì)年齡≥65歲的賁門失弛緩癥患者行POEM安全、有效,該研究對(duì)患者進(jìn)行了為期39個(gè)月的術(shù)后隨訪,發(fā)現(xiàn)患者術(shù)后LESP、Eckardt評(píng)分以及食管平均直徑均較術(shù)前顯著下降(27.4 mm Hg對(duì)9.6 mm Hg; 8.0對(duì)1.0; 51.0 mm對(duì)30.0 mm),且無嚴(yán)重并發(fā)癥發(fā)生。
3. 小兒賁門失弛緩癥患者:關(guān)于小兒賁門失弛緩癥患者施行POEM的報(bào)道較少,一項(xiàng)臨床研究[28]顯示,POEM對(duì)小兒賁門失弛緩癥患者具有較好的臨床療效,可減輕患兒癥狀,術(shù)前和術(shù)后Eckardt評(píng)分差異顯著(8.3對(duì)0.7),平均LESP亦從術(shù)前31.6 mm Hg降至術(shù)后12.9 mm Hg,且不良事件發(fā)生率較低。該試驗(yàn)患兒的年齡為6~17歲,平均13.8歲,平均隨訪時(shí)間24.6個(gè)月。Li等[29]和Tang等[30]的研究亦得出相似結(jié)論,研究表明對(duì)小兒賁門失弛緩癥患者施行POEM可有效緩解患兒臨床癥狀,降低LESP以及Eckardt評(píng)分。近期Zhang等[31]報(bào)道了對(duì)1例11個(gè)月齡的賁門失弛緩癥患兒實(shí)施POEM,該患兒同時(shí)伴有重度營(yíng)養(yǎng)不良、反復(fù)肺部感染。手術(shù)操作流程與成人相似,但在距胃食管交界處上方5 cm處食管5~6點(diǎn)鐘方向進(jìn)行黏膜下注射,縱行切開至賁門下1 cm,術(shù)后166 d隨訪內(nèi)鏡復(fù)查示食管輕度擴(kuò)張,患兒未再出現(xiàn)反復(fù)肺部感染、嘔吐,體質(zhì)量明顯增加,此報(bào)道對(duì)年齡較小的賁門失弛緩癥患者的治療有重要的臨床指導(dǎo)價(jià)值。
4. 乙狀結(jié)腸型賁門失弛緩癥患者:乙狀結(jié)腸型賁門失弛緩癥通常被認(rèn)為是一種進(jìn)展期狀態(tài),食管管腔嚴(yán)重?cái)U(kuò)張、扭曲,給治療造成較大困難。目前認(rèn)為對(duì)于乙狀結(jié)腸型賁門失弛緩癥患者應(yīng)優(yōu)先考慮行內(nèi)鏡下肌切開術(shù),其次再考慮行食管切除術(shù)。Hu等[32]對(duì)32例行POEM的乙狀結(jié)腸型賁門失弛緩癥患者進(jìn)行研究,該研究表明盡管食管嚴(yán)重變形使建立黏膜下隧道存在困難,導(dǎo)致手術(shù)時(shí)間明顯延長(zhǎng),但長(zhǎng)達(dá)30個(gè)月的術(shù)后隨訪顯示,96.8%的患者取得了較好療效,且無嚴(yán)重并發(fā)癥發(fā)生,術(shù)后反流率為25.8%。
由于內(nèi)鏡隧道技術(shù)的出現(xiàn),POEM作為一種新型治療賁門失弛緩癥的手段在臨床上廣泛應(yīng)用。POEM在微創(chuàng)的前提下,顯著縮短了手術(shù)時(shí)間,有效緩解患者臨床癥狀。對(duì)于采用其他方法治療失敗的賁門失弛緩癥患者,實(shí)施POEM仍可取得一定療效。并且該術(shù)式拓寬了賁門失弛緩癥患者的治療范圍,可用于一些特殊患者,如Ⅲ型賁門失弛緩癥、高齡、小兒、乙狀結(jié)腸型賁門失弛緩癥等。
1 Pandolfino JE, Gawron AJ. Achalasia: a systematic review[J]. JAMA, 2015, 313 (18): 1841-1852.
2 Campos GM, Vittinghoff E, Rabl C, et al. Endoscopic and surgical treatments for achalasia: a systematic review and meta-analysis[J]. Ann Surg, 2009, 249 (1): 45-57.
3 Boeckxstaens GE, Zaninotto G, Richter JE. Achalasia[J]. Lancet, 2014, 383 (9911): 83-93.
4 Eckardt VF, Gockel I, Bernhard G. Pneumatic dilation for achalasia: late results of a prospective follow up investigation[J]. Gut, 2004, 53 (5): 629-633.
5 Zhao JG, Li YD, Cheng YS, et al. Long-term safety and outcome of a temporary self-expanding metallic stent for achalasia: a prospective study with a 13-year single-center experience[J]. Eur Radiol, 2009, 19 (8): 1973-1980.
6 Pandolfino JE, Gawron AJ; MSCI. JAMA patient patient: Achalasia[J]. JAMA, 2015, 313 (18): 1876.
7 Phalanusitthepha C, Inoue H, Ikeda H, et al. Peroral endoscopic myotomy for esophageal achalasia[J]. Ann Transl Med, 2014, 2 (3): 31.
8 Cai MY, Zhou PH, Yao LQ, et al. Peroral endoscopic myotomy for idiopathic achalasia: randomized comparison of water-jet assisted versus conventional dissection technique[J]. Surg Endosc, 2014, 28 (4): 1158-1165.
9 Liu BR, Song JT, Omar Jan M. Video of the month. Modified peroral endoscopic myotomy[J]. Am J Gastroenterol, 2015, 110 (4): 499.
10 Yang D, Zhang Q, Draganov PV. Successful placement of a fully covered esophageal stent to bridge a difficult-to-close mucosal incision during peroral endoscopic myotomy[J]. Endoscopy, 2014, 46 Suppl 1 UCTN: E467-E468.
11 Khashab MA, El Zein M, Kumbhari V, et al. Comprehensive analysis of efficacy and safety of peroral endoscopic myotomy performed by a gastroenterologist in the endoscopy unit: a single-center experience[J]. Gastrointest Endosc, 2016, 83 (1): 117-125.
12 Friedel D, Modayil R, Iqbal S, et al. Per-oral endoscopic myotomy for achalasia: An American perspective[J]. World J Gastrointest Endosc, 2013, 5 (9): 420-427.
13 Minami H, Isomoto H, Yamaguchi N, et al. Peroral endoscopic myotomy for esophageal achalasia: clinical impact of 28 cases[J]. Dig Endosc, 2014, 26 (1): 43-51.
14 Barbieri LA, Hassan C, Rosati R, et al. Systematic review and meta-analysis: Efficacy and safety of POEM for achalasia[J]. United European Gastroenterol J, 2015, 3 (4): 325-334.
15 Teitelbaum EN, Soper NJ, Santos BF, et al. Symptomatic and physiologic outcomes one year after peroral esophageal myotomy (POEM) for treatment of achalasia[J]. Surg Endosc, 2014, 28 (12): 3359-3365.
16 Werner YB, Costamagna G, Swanstr?m LL, et al. Clinical response to peroral endoscopic myotomy in patients with idiopathic achalasia at a minimum follow-up of 2 years[J]. Gut, 2016, 65 (6): 899-906.
17 晉弘,張莉莉,鄭忠青,等. 經(jīng)口內(nèi)鏡下肌切開術(shù)治療賁門失弛緩癥術(shù)后3年療效評(píng)估[J].中華消化雜志, 2015, 35 (4): 217-220.
18 Ren Z, Zhong Y, Zhou P, et al. Perioperative management and treatment for complications during and after peroral endoscopic myotomy (POEM) for esophageal achalasia (EA) (data from 119 cases)[J]. Surg Endosc, 2012, 26 (11): 3267-3272.
19 Bhayani NH, Kurian AA, Dunst CM, et al. A comparative study on comprehensive, objective outcomes of laparoscopic Heller myotomy with per-oral endoscopic myotomy (POEM) for achalasia[J]. Ann Surg, 2014, 259 (6): 1098-1103.
20 Patel K, Abbassi-Ghadi N, Markar S, et al. Peroral endoscopic myotomy for the treatment of esophageal achalasia: systematic review and pooled analysis[J]. Dis Esophagus, 2016, 29 (7): 807-819.
21 Shiwaku H, Inoue H, Sasaki T, et al. A prospective analysis of GERD after POEM on anterior myotomy[J]. Surg Endosc, 2016, 30 (6): 2496-2504.
22 Wei M, Yang T, Yang X, et al. Peroral esophageal myotomy versus laparoscopic Heller’s myotomy for achalasia: a meta-analysis[J]. J Laparoendosc Adv Surg Tech A, 2015, 25 (2): 123-129.
23 Onimaru M, Inoue H, Ikeda H, et al. Peroral endoscopic myotomy is a viable option for failed surgical esophagocardiomyotomy instead of redo surgical Heller myotomy: a single center prospective study[J]. J Am Coll Surg, 2013, 217 (4): 598-605.
24 鄧治良,姜泊. 經(jīng)口內(nèi)鏡下肌切開術(shù)與球囊擴(kuò)張治療賁門失弛緩癥的療效比較[J]. 中國(guó)臨床醫(yī)師雜志(電子版), 2015, 9 (12): 2323-2326.
25 Ling T, Guo H, Zou X. Effect of peroral endoscopic myotomy in achalasia patients with failure of prior pneumatic dilation: a prospective case-control study[J]. J Gastroenterol Hepatol, 2014, 29 (8): 1609-1613.
26 Kumbhari V, Tieu AH, Onimaru M, et al. Peroral endoscopic myotomy (POEM)vslaparoscopic Heller myotomy (LHM) for the treatment of Type Ⅲ achalasia in 75 patients: a multicenter comparative study[J]. Endosc Int Open, 2015, 3 (3): E195-E201.
27 Li CJ, Tan YY, Wang XH, et al. Peroral endoscopic myotomy for achalasia in patients aged ≥ 65 years[J]. World J Gastroenterol, 2015, 21 (30): 9175-9181.
28 Chen WF, Li QL, Zhou PH, et al. Long-term outcomes of peroral endoscopic myotomy for achalasia in pediatric patients: a prospective, single-center study[J]. Gastrointest Endosc, 2015, 81 (1): 91-100.
29 Li C, Tan Y, Wang X, et al. Peroral endoscopic myotomy for treatment of achalasia in children and adolescents[J]. J Pediatr Surg, 2015, 50 (1): 201-205.
30 Tang X, Gong W, Deng Z, et al. Usefulness of peroral endoscopic myotomy for treating achalasia in children: experience from a single center[J]. Pediatr Surg Int, 2015, 31 (7): 633-638.
31 Zhang XC, Li QL, Huang Y, et al. Peroral endoscopic myotomy using the posterior approach in an 11-month-old girl with achalasia, severe malnutrition, and recurrent pneumonia[J]. Endoscopy, 2015, 47 Suppl 1 UCTN: E480-E482.
32 Hu JW, Li QL, Zhou PH, et al. Peroral endoscopic myotomy for advanced achalasia with sigmoid-shaped esophagus: long-term outcomes from a prospective, single-center study[J]. Surg Endosc, 2015, 29 (9): 2841-2850.
(2016-04-07收稿;2016-04-21修回)
Current Status and Progress of Peroral Endoscopic Myotomy in Treatment of Achalasia of Cardia
LIFenting,GAOXinxin,WANGXin,XIEHuahong.
DepartmentofDigestiveDiseases,XijingHospital,FourthMilitaryMedicalUniversity,Xian(710032)
XIE Huahong, Email: fangfang1@fmmu.edu.cn
Achalasia of cardia caused by neuromuscular dysfunction at esophagus-stomach junction is a functional disease of esophageal dynamic dysfunction. It is characterized by absence of peristalsis of esophageal body and failure of the lower esophageal sphincter to relax. The methods of therapy include botulinum toxin injection, stent placement, laparoscopic Heller myotomy and balloon dilatation. However, these methods have some shortages, such as easy to recur, causing larger trauma, etc.. With the development of technology of endoscopy, a new method peroral endoscopic myotomy (POEM) is widely used in clinical practice, and it can used in some special patients such as Ⅲ type achalasia, pediatric and elderly patients, as well as sigmoid-type achalasia. This article reviewed the current status and progress of POEM in treatment of achalasia of cardia.
Achalasia of Cardia; Peroral Endoscopic Myotomy; Therapy; Postoperative Complications
10.3969/j.issn.1008-7125.2017.01.013
*本文通信作者,Email: fangfang1@fmmu.edu.cn